摘要
药物基因组学是一门从基因水平预测药物疗效及毒性的新兴学科,旨在阐释药物疗效和毒性的个体差异,指导个体化用药,尽量避免药物不良反应和耐药现象的发生。肿瘤药物基因组学的主要研究对象是人体内与抗肿瘤药物反应相关的生物标志物,包括药物代谢酶、药物作用靶标以及药物转运体等。生物标志物的基因多态性是导致药物反应因人而异的关键因素,单核苷酸多态性则是基因多态性的一种重要形式。本文通过总结肿瘤生物标志物的基因多态性,分析抗肿瘤药物在药效、毒性和耐药方面的个体化差异,探讨肿瘤药物基因组学的研究进展,为临床用药提供参考。
Pharmacogenomics is a burgeoning discipline forecasting drug effect and toxicity at gene level. It aims to explain individual differences in drug efficacy and toxicity, guide individual treatment, and minimize adverse drug reaction and drug resistance. The main object of this subject is tumor biological markers associated with anti-cancer drugs in human body, including drug metabolizing enzymes, drug targets and drug transporters. As is known to all, genetic polymorphism of biomarkers is the key factor leading to individual differences in drug reactions, and single nucleotide polymorphisms is an important form of genetic polymorphism. This paper summarizs the genetic polymorphism of biomarkers associated with tumor, analyzes individual differences in anti-cancer drug efficacy, toxicity and resistance, research progresses in pharmacogenomics of anti-cancer drugs, and provides reference for clinical medical treatment.
出处
《国际药学研究杂志》
CAS
CSCD
2014年第1期51-56,4,共6页
Journal of International Pharmaceutical Research
关键词
药物基因组学
生物标志物
基因多态性
药物代谢酶
pharmacogenomics
biological marker
genetic polymorphism
drug metabolizing enzyme
